Inovio agrees to pay shareholders $44M in cash and stock to settle lawsuit tied to Covid vaccine candidate


The lawsuit was filed against Inovio and its former CEO J. Joseph Kim in March 2020.

Previous At these veterinary schools, women leaders are tackling the challenges of the profession
Next Lab Notes: Teleflex making acquisition valued at up to $300M; Vyant Bio files delayed quarterly report